DOCSLIB.ORG

Ventricular Tissue Culture Model for Cardiovascular

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ventricular Tissue Culture Model for Cardiovascular VENTRICULAR TISSUE CULTURE MODEL FOR CARDIOVASCULAR RESEARCH KRISTY PURNAMAWATI (B. Eng., NUS) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY NUS GRADUATE SCHOOL FOR INTEGRATIVE SCIENCES AND ENGINEERING NATIONAL UNIVERSITY OF SINGAPORE 2015 DECLARATION I hereby declare that this thesis is my original work and it has been written by me in its entirety. I have duly acknowledged all the sources of information which have been used in the thesis. This thesis has also not been previously submitted for any degree in any university. _________________________ Kristy Purnamawati 06 May 2015 ii ACKNOWLEDGEMENTS The completion of this thesis will not be possible without the kind and generous help from so many people both in Singapore and Germany. I wish to express my most sincere gratitude to my supervisors and mentors Dr. William Sun, Prof. E. Birgitte Lane, A/Prof. Cao Tong, Prof. Dr. Wolfram H. Zimmermann, Dr. Poh Loong Soong and Dr. Malte Tiburcy for their invaluable guidance, intellectual input and constant support throughout the course of my study. My special thanks go out to the Zimmermann lab in Göttingen for welcoming me to be part their lab for a good portion of the project. I would also like to thank A*STAR Graduate Academy (AGA), Deutsches Zentrum für Herz-Kreislauf-Forschung E.V. (DZHK) and Deutsche Forschungsgemeinschaft (DFG) for their financial support, as well as NGS, NUS for facilitating the multitudes of change that occurred throughout this PhD journey. This work was completed in 27 months, from conception to last day of data collection. I am very grateful to my family and friends for their love and encouragement. It kept me going. YHJ, this work is for you. RIP. iii TABLE OF CONTENT TITLE PAGE ................................................................................................................... i DECLARATION ............................................................................................................. ii ACKNOWLEDGEMENTS ............................................................................................... iii TABLE OF CONTENT .................................................................................................... iv SUMMARY ................................................................................................................. vi LIST OF FIGURES ......................................................................................................... ix LIST OF TABLES .......................................................................................................... xiii LIST OF APPENDICES ................................................................................................... xv LIST OF ABBREVIATIONS ............................................................................................ xvi PUBLICATIONS, PRESENTATIONS AND AWARDS .......................................................... xvii CHAPTER 1 ........................................................................................................................... 18 General Introduction 1.1. Introduction ........................................................................................................... 19 1.2. References ............................................................................................................. 23 CHAPTER 2 ...........................................................................................................................25 Differentiation of hPSCs to Cardiomyocytes and Generation of Engineered Heart Muscles (EHMs) 2.1. Abstract ................................................................................................................ 28 2.2. Introduction and Literature review ..................................................................... 29 2.3. Materials and Methods ........................................................................................ 43 2.4. Results .................................................................................................................. 54 2.5. Discussion ............................................................................................................. 67 2.6. References ........................................................................................................... 78 CHAPTER 3 ........................................................................................................................... 85 Engineering and Functional Validation of MYL2- Knock-In Reporter Line 3.1. Abstract .................................................................................................................. 88 3.2. Introduction and Literature review ....................................................................... 90 3.3. Materials and Methods .......................................................................................... 96 3.4. Results .................................................................................................................. 116 3.5. Discussion ............................................................................................................. 144 3.6. References ........................................................................................................... 150 iv CHAPTER 4 ......................................................................................................................... 153 In vitro Maturation of HESCs-derived Cardiomyocytes 4.1. Abstract ................................................................................................................ 156 4.2. Introduction and literature review ...................................................................... 158 4.3. Materials and Methods ........................................................................................ 172 4.4. Results .................................................................................................................. 175 4.5. Discussion ............................................................................................................. 219 4.6. References ........................................................................................................... 225 CHAPTER 5 ......................................................................................................................... 231 Utility of in vitro Ventricular Cardiomyocytes Model 5.1. Abstract ................................................................................................................ 233 5.2. Introduction and literature review ...................................................................... 235 5.3. Materials and Methods ........................................................................................ 239 5.4. Results .................................................................................................................. 241 5.5. Discussion ............................................................................................................. 269 5.6. References ........................................................................................................... 278 CHAPTER 6 ......................................................................................................................... 281 General Conclusion and Future Directions APPENDICES ............................................................................................................. 286 v SUMMARY The ventricles of the heart are the chambers responsible for pumping blood into the lungs as well as the entire body. In these chambers of the heart, the working myocytes are termed ventricular cardiomyocytes (vCMs). Diseases associated with the ventricular chambers of the heart such as ventricular fibrillation, myocardial infarction and cardiomyopathy would ultimately affect the properties and functions of these vCMs. Limited supply (Peeters et al., 1995) and the lack of regenerative capacity of adult human vCMs limit their utility for in vitro studies (Mummery, 2005). Therefore, a vCM-specific in vitro model would be a useful tool for the development of therapies for ventricular chambers-associated diseases. In addition, the vCM in vitro model can also be used in cardiotoxicity drug screening, to screen newly developed drugs for ventricular pro-arrhythmic liability. In this study, human embryonic stem cells (hESCs) are used as the source of cardiomyocytes (CMs). However, cardiac differentiation of hESCs gives rise to all three subtypes of CMs. In addition, these hESCs-derived CMs are phenotypically immature, closest to fetal or at best, neonatal CMs in characteristic. To facilitate the fractionation of vCMs from a pool of mixed hESCs-derived CMs, an MYL2 specific knock-in reporter line was developed. MYL2 has been reported to be specifically expressed in vCMs and not atrial cardiomyocytes (Bird, 2003; Zhang et al., 2011). The knock-in line was generated with homologous-recombination technique with the aid of a novel genome editing tool: transcription activator-like effector nuclease (TALEN). Two reporters (mCherry and Gaussia Luciferase) and one selectable marker (neomycin resistance) were knocked into the last exon of MYL2 gene, behind the coding sequence of the gene. PCR and Southern blotting confirmed that the targeting construct was inserted at the correct site. Immunohistochemistry and FACS analysis, together with karyotype data, also vi confirmed that the knock-in lines are pluripotent and do not show any gross chromosomal aberrations. Functional validation
Load more

Recommended publications
  • In Silico Prediction of High-Resolution Hi-C Interaction Matrices
    ARTICLE https://doi.org/10.1038/s41467-019-13423-8 OPEN In silico prediction of high-resolution Hi-C interaction matrices Shilu Zhang1, Deborah Chasman 1, Sara Knaack1 & Sushmita Roy1,2* The three-dimensional (3D) organization of the genome plays an important role in gene regulation bringing distal sequence elements in 3D proximity to genes hundreds of kilobases away. Hi-C is a powerful genome-wide technique to study 3D genome organization. Owing to 1234567890():,; experimental costs, high resolution Hi-C datasets are limited to a few cell lines. Computa- tional prediction of Hi-C counts can offer a scalable and inexpensive approach to examine 3D genome organization across multiple cellular contexts. Here we present HiC-Reg, an approach to predict contact counts from one-dimensional regulatory signals. HiC-Reg pre- dictions identify topologically associating domains and significant interactions that are enri- ched for CCCTC-binding factor (CTCF) bidirectional motifs and interactions identified from complementary sources. CTCF and chromatin marks, especially repressive and elongation marks, are most important for HiC-Reg’s predictive performance. Taken together, HiC-Reg provides a powerful framework to generate high-resolution profiles of contact counts that can be used to study individual locus level interactions and higher-order organizational units of the genome. 1 Wisconsin Institute for Discovery, 330 North Orchard Street, Madison, WI 53715, USA. 2 Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53715, USA. *email: [email protected] NATURE COMMUNICATIONS | (2019) 10:5449 | https://doi.org/10.1038/s41467-019-13423-8 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13423-8 he three-dimensional (3D) organization of the genome has Results Temerged as an important component of the gene regulation HiC-Reg for predicting contact count using Random Forests.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • 0008-5472.CAN-11-3506.Full-Text.Pdf
    Author Manuscript Published OnlineFirst on November 14, 2011; DOI: 10.1158/0008-5472.CAN-11-3506 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer Sandra D. Castillo1, Ander Matheu2, Niccolo Mariani1, Julian Carretero3, Fernando Lopez- Rios4, Robin Lovell-Badge2 and Montse Sanchez-Cespedes1* Authors´Affiliations:1Genes and Cancer Group, Cancer Epigenetics and Biology Program- PEBC), Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain. 2Division of Stem Cell Biology and Developmental Genetics, MRC National Institute for Medical Research, London, UK. 3Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, Spain. 4Hospital Universitario Madrid-Sanchinarro, Laboratorio Dianas Terapeuticas, Madrid, Spain Running title: Novel SOX4 targets and small cell lung cancer development Keywords: SCLC, SOX4, SOX11, neuroendocrine lung tumors, oncogene Disclosure of potential conflict of interest: No conflicts of interest were disclosed. Word count: 5,428 Total number of figures and tables: 6 Accession number: Array data deposited in the Gene Expression Omnibus (GEO) under accession number GSE31612. *Corresponding Author: Montse Sanchez-Cespedes, Cancer Epigenetics and Biology Program-PEBC (IDIBELL) 08908, Hospitalet de Llobregat, Barcelona, Spain; Tel: +34932607132, Fax: +34932607219, Email: [email protected] 1 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 14, 2011; DOI: 10.1158/0008-5472.CAN-11-3506 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Hippo and Sonic Hedgehog Signalling Pathway Modulation of Human Urothelial Tissue Homeostasis
    Hippo and Sonic Hedgehog signalling pathway modulation of human urothelial tissue homeostasis Thomas Crighton PhD University of York Department of Biology November 2020 Abstract The urinary tract is lined by a barrier-forming, mitotically-quiescent urothelium, which retains the ability to regenerate following injury. Regulation of tissue homeostasis by Hippo and Sonic Hedgehog signalling has previously been implicated in various mammalian epithelia, but limited evidence exists as to their role in adult human urothelial physiology. Focussing on the Hippo pathway, the aims of this thesis were to characterise expression of said pathways in urothelium, determine what role the pathways have in regulating urothelial phenotype, and investigate whether the pathways are implicated in muscle-invasive bladder cancer (MIBC). These aims were assessed using a cell culture paradigm of Normal Human Urothelial (NHU) cells that can be manipulated in vitro to represent different differentiated phenotypes, alongside MIBC cell lines and The Cancer Genome Atlas resource. Transcriptomic analysis of NHU cells identified a significant induction of VGLL1, a poorly understood regulator of Hippo signalling, in differentiated cells. Activation of upstream transcription factors PPARγ and GATA3 and/or blockade of active EGFR/RAS/RAF/MEK/ERK signalling were identified as mechanisms which induce VGLL1 expression in NHU cells. Ectopic overexpression of VGLL1 in undifferentiated NHU cells and MIBC cell line T24 resulted in significantly reduced proliferation. Conversely, knockdown of VGLL1 in differentiated NHU cells significantly reduced barrier tightness in an unwounded state, while inhibiting regeneration and increasing cell cycle activation in scratch-wounded cultures. A signalling pathway previously observed to be inhibited by VGLL1 function, YAP/TAZ, was unaffected by VGLL1 manipulation.
    [Show full text]
  • A Discovery Resource of Rare Copy Number Variations in Individuals with Autism Spectrum Disorder
    INVESTIGATION A Discovery Resource of Rare Copy Number Variations in Individuals with Autism Spectrum Disorder Aparna Prasad,* Daniele Merico,* Bhooma Thiruvahindrapuram,* John Wei,* Anath C. Lionel,*,† Daisuke Sato,* Jessica Rickaby,* Chao Lu,* Peter Szatmari,‡ Wendy Roberts,§ Bridget A. Fernandez,** Christian R. Marshall,*,†† Eli Hatchwell,‡‡ Peggy S. Eis,‡‡ and Stephen W. Scherer*,†,††,1 *The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto M5G 1L7, Canada, †Department of Molecular Genetics, University of Toronto, Toronto M5G 1L7, Canada, ‡Offord Centre for Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton L8P 3B6, § Canada, Autism Research Unit, The Hospital for Sick Children, Toronto M5G 1X8, Canada, **Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland A1B 3V6, Canada, ††McLaughlin Centre, University of Toronto, Toronto M5G 1L7, Canada, and ‡‡Population Diagnostics, Inc., Melville, New York 11747 ABSTRACT The identification of rare inherited and de novo copy number variations (CNVs) in human KEYWORDS subjects has proven a productive approach to highlight risk genes for autism spectrum disorder (ASD). A rare variants variety of microarrays are available to detect CNVs, including single-nucleotide polymorphism (SNP) arrays gene copy and comparative genomic hybridization (CGH) arrays. Here, we examine a cohort of 696 unrelated ASD number cases using a high-resolution one-million feature CGH microarray, the majority of which were previously chromosomal genotyped with SNP arrays. Our objective was to discover new CNVs in ASD cases that were not detected abnormalities by SNP microarray analysis and to delineate novel ASD risk loci via combined analysis of CGH and SNP array cytogenetics data sets on the ASD cohort and CGH data on an additional 1000 control samples.
    [Show full text]
  • Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer
    Published OnlineFirst November 14, 2011; DOI: 10.1158/0008-5472.CAN-11-3506 Cancer Molecular and Cellular Pathobiology Research Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer Sandra D. Castillo1, Ander Matheu2, Niccolo Mariani1, Julian Carretero3, Fernando Lopez-Rios4, Robin Lovell-Badge2, and Montse Sanchez-Cespedes1 Abstract The HMG box transcription factor SOX4 involved in neuronal development is amplified and overexpressed in a subset of lung cancers, suggesting that it may be a driver oncogene. In this study, we sought to develop this hypothesis including by defining targets of SOX4 that may mediate its involvement in lung cancer. Ablating SOX4 expression in SOX4-amplified lung cancer cells revealed a gene expression signature that included genes involved in neuronal development such as PCDHB, MYB, RBP1, and TEAD2. Direct recruitment of SOX4 to gene promoters was associated with their upregulation upon ectopic overexpression of SOX4. We confirmed upregulation of the SOX4 expression signature in a panel of primary lung tumors, validating their specific response by a comparison using embryonic fibroblasts from Sox4-deficient mice. Interestingly, we found that small cell lung cancer (SCLC), a subtype of lung cancer with neuroendocrine characteristics, was generally characterized by high levels of SOX2, SOX4, and SOX11 along with the SOX4-specific gene expression signature identified. Taken together, our findings identify a functional role for SOX genes in SCLC, particularly for SOX4 and several novel targets defined in this study. Cancer Res; 72(1); 1–11. Ó2011 AACR. Introduction on chromosome 6p22, containing the SOX4 gene, which was expressed at very high levels and was the best candidate for an As with other types of cancer, lung cancer is undergoing a oncogene in the amplicon (2).
    [Show full text]
  • ARHGDIG / RHOGDI-3 Antibody (C-Terminus) Goat Polyclonal Antibody Catalog # ALS15383
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ARHGDIG / RHOGDI-3 Antibody (C-Terminus) Goat Polyclonal Antibody Catalog # ALS15383 Specification ARHGDIG / RHOGDI-3 Antibody (C-Terminus) - Product Information Application WB, IHC Primary Accession Q99819 Reactivity Human, Monkey, Dog Host Goat Clonality Polyclonal Calculated MW 25kDa KDa ARHGDIG / RHOGDI-3 Antibody (C-Terminus) - Additional Information Gene ID 398 ARHGDIG antibody (0.5 ug/ml) staining of HeLa lysate (35 ug protein/ml in RIPA buffer). Other Names Rho GDP-dissociation inhibitor 3, Rho GDI 3, Rho-GDI gamma, ARHGDIG Target/Specificity Human ARHGDIG. Reconstitution & Storage Store at -20°C. Minimize freezing and thawing. Precautions ARHGDIG / RHOGDI-3 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-ARHGDIG / RHOGDI-3 antibody IHC of human brain, cortex. ARHGDIG / RHOGDI-3 Antibody (C-Terminus) - Protein Information ARHGDIG / RHOGDI-3 Antibody (C-Terminus) - Background Name ARHGDIG Inhibits GDP/GTP exchange reaction of RhoB. Function Interacts specifically with the GDP- and Inhibits GDP/GTP exchange reaction of GTP-bound forms of post- translationally RhoB. Interacts specifically with the GDP- processed Rhob and Rhog proteins, both of and GTP-bound forms of post-translationally which show a growth-regulated expression in processed Rhob and Rhog proteins, both of mammalian cells. Stimulates the release of the which show a growth-regulated expression GDP-bound but not the GTP-bound RhoB in mammalian cells. Stimulates the release protein. Also inhibits the GDP/GTP exchange of of the GDP-bound but not the GTP-bound RhoB but shows less ability to inhibit the Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 RhoB protein.
    [Show full text]
  • The Disruption Ofcelf6, a Gene Identified by Translational Profiling
    2732 • The Journal of Neuroscience, February 13, 2013 • 33(7):2732–2753 Neurobiology of Disease The Disruption of Celf6, a Gene Identified by Translational Profiling of Serotonergic Neurons, Results in Autism-Related Behaviors Joseph D. Dougherty,1,2 Susan E. Maloney,1,2 David F. Wozniak,2 Michael A. Rieger,1,2 Lisa Sonnenblick,3,4,5 Giovanni Coppola,4 Nathaniel G. Mahieu,1 Juliet Zhang,6 Jinlu Cai,8 Gary J. Patti,1 Brett S. Abrahams,8 Daniel H. Geschwind,3,4,5 and Nathaniel Heintz6,7 Departments of 1Genetics and 2Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, 3UCLA Center for Autism Research and Treatment, Semel Institute for Neuroscience and Behavior, 4Program in Neurogenetics, Department of Neurology, and 5Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, 6Laboratory of Molecular Biology, Howard Hughes Medical Institute, and 7The GENSAT Project, Rockefeller University, New York, New York 10065, and 8Departments of Genetics and Neuroscience, Albert Einstein College of Medicine, New York, New York 10461 The immense molecular diversity of neurons challenges our ability to understand the genetic and cellular etiology of neuropsychiatric disorders. Leveraging knowledge from neurobiology may help parse the genetic complexity: identifying genes important for a circuit that mediates a particular symptom of a disease may help identify polymorphisms that contribute to risk for the disease as a whole. The serotonergic system has long been suspected in disorders that have symptoms of repetitive behaviors and resistance to change, including autism. We generated a bacTRAP mouse line to permit translational profiling of serotonergic neurons.
    [Show full text]
  • Mir-34/449 Control Apical Actin Network Formation During Multiciliogenesis Through Small Gtpase Pathways
    ARTICLE Received 7 Jul 2015 | Accepted 17 Aug 2015 | Published 18 Sep 2015 DOI: 10.1038/ncomms9386 OPEN miR-34/449 control apical actin network formation during multiciliogenesis through small GTPase pathways Benoıˆt Chevalier1,2,*, Anna Adamiok3,*, Olivier Mercey1,2,*, Diego R. Revinski3, Laure-Emmanuelle Zaragosi1,2, Andrea Pasini3, Laurent Kodjabachian3, Pascal Barbry1,2 & Brice Marcet1,2 Vertebrate multiciliated cells (MCCs) contribute to fluid propulsion in several biological processes. We previously showed that microRNAs of the miR-34/449 family trigger MCC differentiation by repressing cell cycle genes and the Notch pathway. Here, using human and Xenopus MCCs, we show that beyond this initial step, miR-34/449 later promote the assembly of an apical actin network, required for proper basal bodies anchoring. Identification of miR-34/449 targets related to small GTPase pathways led us to characterize R-Ras as a key regulator of this process. Protection of RRAS messenger RNA against miR-34/449 binding impairs actin cap formation and multiciliogenesis, despite a still active RhoA. We propose that miR-34/449 also promote relocalization of the actin binding protein Filamin-A, a known RRAS interactor, near basal bodies in MCCs. Our study illustrates the intricate role played by miR-34/449 in coordinating several steps of a complex differentiation programme by regulating distinct signalling pathways. 1 CNRS, Institut de Pharmacologie Mole´culaire et Cellulaire (IPMC), UMR-7275, 660 route des Lucioles, 06560 Sophia-Antipolis, France. 2 University of Nice-Sophia-Antipolis (UNS), Institut de Pharmacologie Mole´culaire et Cellulaire, 660 route des Lucioles, Valbonne, 06560 Sophia-Antipolis, France.
    [Show full text]